For laboratory research use only — not for human or veterinary use. Not evaluated by the U.S. FDA.
Cellular Peptide
SS-31
A mitochondria-targeting tetrapeptide with affinity for cardiolipin on the inner mitochondrial membrane, studied in preclinical models for effects on mitochondrial bioenergetics.
Size
Quantity
$74.99
Bundle & save
Delivery
Order by 3:00 PM ET for same-day dispatch
Cutoff 3:00 PM ET · same-day dispatch
Estimated arrival in 2–3 business days
Overnight shipping available
Free shipment protection included
SS-31
1 × 10mg · $74.99
99% purity, QC passed
HPLC + mass-spec verified
Shipment protection
Free on every order
Free shipping over $150
Same-day dispatch before 3PM ET
Certificate of Analysis
Third-party tested · Independent analytical lab
10mg
99.83%latest
| Tested | Measured | Purity |
|---|---|---|
| Jun 2026 | 10.73mg | 99.83% |
| May 2026 | 11.12mg | 99.77% |
| Apr 2026 | 10.87mg | 99.86% |
| Feb 2026 | 13.65mg | 99.69% |
| Jan 2026 | 10.64mg | 99.64% |
| Dec 2025 | 10.54mg | 99.42% |
| Nov 2025 | 14.40mg | 99.60% |
50mg
99.79%latest
| Tested | Measured | Purity |
|---|---|---|
| Jul 2026 | 51.89mg | 99.79% |
| Jun 2026 | 53.71mg | 99.82% |
| May 2026 | 50.58mg | 99.80% |
| Mar 2026 | 53.34mg | 99.92% |
| Jan 2026 | 48.75mg | 99.73% |
| Jan 2026 | 51.21mg | 99.76% |
| Dec 2025 | 49.88mg | 99.85% |
| Dec 2025 | 47.72mg | 99.27% |
| Nov 2025 | 60.76mg | 99.69% |
Frequently researched together
Commonly studied alongside SS-31.
Compound information
Technical specifications
Molecular profile
| Type | Mitochondria-targeted tetrapeptide |
| CAS number | 736992-21-5 |
| Molecular weight | 639.8 g/mol |
| Amino acids | 4 |
| Sequence | D-Arg-Dmt-Lys-Phe-NH2 |
| Formula | C32H49N9O5 |
Storage & stability
- ❄️
Lyophilized (powder)
-20°C · stable 2+ years
- ❄️
Reconstituted
2–8°C · use within 30 days
Sources & references
Peer-reviewed literature, for research context
- International journal of molecular sciences
Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential
2025·DOI: 10.3390/ijms26030944·PMID: 39940712Tung C, Varzideh F, Farroni E, Mone P, Kansakar U, Jankauskas SS
View source - Neurology
Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial
2023·DOI: 10.1212/WNL.0000000000207402·PMID: 37268435Karaa A, Bertini E, Carelli V, Cohen BH, Enns GM, Falk MJ
View source - Journal of neuroinflammation
Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice
2019·DOI: 10.1186/s12974-019-1627-9·PMID: 31747905Zhao W, Xu Z, Cao J, Fu Q, Wu Y, Zhang X
View source - Proceedings of the National Academy of Sciences of the United States of America
Mitochondrial protein interaction landscape of SS-31
2020·DOI: 10.1073/pnas.2002250117·PMID: 32554501Chavez JD, Tang X, Campbell MD, Reyes G, Kramer PA, Stuppard R
View source
Important research notice
Not for human consumption. This product is sold exclusively for laboratory and in vitro research. It is not intended to diagnose, treat, cure, or prevent any disease.
Any research findings referenced on this page are drawn from published, peer-reviewed literature and are provided for educational context only. They are not product claims and should not be read as medical advice.
By purchasing, you confirm you are a qualified researcher and will handle this material in accordance with all applicable laws and institutional guidelines.